BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp decreased its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 12.9% during the third quarter, HoldingsChannel reports. The firm owned 319,466 shares of the company’s stock after selling 47,235 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Kenvue were worth $7,389,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its position in Kenvue by 53.7% during the 1st quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock worth $3,541,000 after acquiring an additional 57,679 shares during the last quarter. Atria Investments Inc boosted its stake in Kenvue by 20.0% during the 1st quarter. Atria Investments Inc now owns 112,194 shares of the company’s stock valued at $2,408,000 after purchasing an additional 18,663 shares during the period. Cetera Investment Advisers grew its holdings in Kenvue by 183.9% in the 1st quarter. Cetera Investment Advisers now owns 449,506 shares of the company’s stock valued at $9,646,000 after buying an additional 291,179 shares during the last quarter. Cetera Advisors LLC grew its holdings in Kenvue by 202.0% in the 1st quarter. Cetera Advisors LLC now owns 212,097 shares of the company’s stock valued at $4,552,000 after buying an additional 141,858 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Kenvue by 78.6% during the first quarter. EverSource Wealth Advisors LLC now owns 4,155 shares of the company’s stock worth $89,000 after buying an additional 1,829 shares during the last quarter. 97.64% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
KVUE has been the topic of a number of research reports. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. UBS Group upped their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Deutsche Bank Aktiengesellschaft upped their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $22.64.
Kenvue Price Performance
Shares of KVUE stock opened at $24.08 on Monday. The stock’s fifty day simple moving average is $22.94 and its 200 day simple moving average is $20.99. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm has a market cap of $46.17 billion, a price-to-earnings ratio of 43.78, a P/E/G ratio of 2.19 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.
Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. The firm’s quarterly revenue was down .4% compared to the same quarter last year. On average, analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- What is Put Option Volume?
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- 5 Top Rated Dividend Stocks to Consider
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- What is the S&P 500 and How It is Distinct from Other Indexes
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.